Manufacturing

The company has three dedicated state-of-the-art production facilities located in Athens Greece, designed in accordance with EU cGMP requirements:

Oncology Sterile Liquid Dosage Forms (inaugurated in 2006)

• Product Form: water-based solutions
• Molecules handled: Carboplatin, Doxorubicin, Epirubicin, Mitoxantrone, Oxaliplatin & Clofarabine
• Compounding Capacity: up to 100L
• Primary Packaging: glass vials with rubber stopper and flip-off cap
• Vials Filling Volume: ranging from 5ml up to 100ml
• Technology: cleanroom, isolator, aseptic filling, terminal sterilization
• Full Capacity: 1 million vials
• Accreditations: EU GMP, Gulf Countries Council (GCC), Health Canada, Therapeutic Goods Administration (TGA-Australia)

Oncology Oral Solid Dosage Forms (inaugurated in 2007)

• Product Forms: tablets (uncoated or coated) & hard gelatin capsules
• Molecules handled: Anastrozole, Bicalutamide, Exemestane, Finasteride, Flutamide, Hydroxyurea, Letrozole, Tamoxifen & Thioguanine
• Granulation Capacity: up to 150kg
• Primary Packaging: blisters
• Full Capacity: 100 million tablets, 10 million capsules
• Accreditations: EU GMP, Gulf Countries Council (GCC), Health Canada, Therapeutic Goods Administration (TGA-Australia)
• Anvisa accreditation
• Russian authorities accreditation

Conventional Solid Dosage Forms (renovated in 2005)

• Product Forms: tablets (uncoated, coated, orodispersible and chewable), hard gelatin capsules.
• Molecules handled: more than thirty-five (35).
• Primary Packaging: blisters.
• Full Capacity: 400 million tablets, 40 million capsules.
• Accreditations: EU GMP, Gulf Countries Council (GCC), Health Canada, Therapeutic Goods Administration (TGA-Australia)
• Anvisa accreditation
• Russian authorities accreditation